Roth Mkm began coverage on shares of Reviva Pharmaceuticals (NASDAQ:RVPH - Free Report) in a report released on Friday,Benzinga reports. The brokerage issued a buy rating and a $7.00 price target on the stock.
Separately, EF Hutton Acquisition Co. I upgraded shares of Reviva Pharmaceuticals to a "strong-buy" rating in a research report on Monday, September 23rd. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Reviva Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $11.25.
View Our Latest Report on RVPH
Reviva Pharmaceuticals Price Performance
Shares of Reviva Pharmaceuticals stock traded up $0.01 on Friday, reaching $1.88. The company had a trading volume of 4,428,758 shares, compared to its average volume of 3,583,320. The firm has a market cap of $62.87 million, a price-to-earnings ratio of -1.69 and a beta of -0.12. The firm's 50-day moving average price is $1.56 and its two-hundred day moving average price is $1.29. Reviva Pharmaceuticals has a 1 year low of $0.60 and a 1 year high of $4.83.
Hedge Funds Weigh In On Reviva Pharmaceuticals
An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC lifted its stake in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) by 17.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 278,496 shares of the company's stock after purchasing an additional 42,376 shares during the period. Geode Capital Management LLC owned about 0.83% of Reviva Pharmaceuticals worth $401,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 63.18% of the company's stock.
About Reviva Pharmaceuticals
(
Get Free Report)
Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.
Featured Articles
Before you consider Reviva Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reviva Pharmaceuticals wasn't on the list.
While Reviva Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
